menu
    • menu
    [{"orgOrder":0,"company":"Imvax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Autologous GBM Cells","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imvax \/ Not Applicable"},{"orgOrder":0,"company":"Imvax","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Undisclosed"},{"orgOrder":0,"company":"Imvax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Inapplicable"},{"orgOrder":0,"company":"Imvax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Inapplicable"},{"orgOrder":0,"company":"Imvax","sponsor":"HP WILD Holding AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Series C Financing","leadProduct":"IGV-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ HP WILD Holding AG","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ HP WILD Holding AG"},{"orgOrder":0,"company":"Imvax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Inapplicable"},{"orgOrder":0,"company":"Imvax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"IGV-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Imvax

    Menu

    Imvax

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGV-001,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Imvax Completes IGV-001 Phase 2b Trial Enrollment And Secures Financing

                            Details : The financing aims to fund the clinical development of IGV-001. Currently, it is being evaluated in the mid-stage clinical trials for treating patients with glioblastoma.

                            Product Name : IGV-001

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            May 21, 2024

                            Lead Product(s) : IGV-001,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGV-001,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imvax Announces First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma

                            Details : IGV-001 is an autologous biologic-device combination product derived from Imvax’s proprietary Goldspire™ immuno-oncology platform for solid tumors. Currently it is being developed for newly diagnosed glioblastoma.

                            Product Name : IGV-001

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            March 27, 2023

                            Lead Product(s) : IGV-001,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGV-001,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 SITC Meeting

                            Details : In the Phase 1b study of IGV-001, multiple efficacy signals were observed including significant improvements in progression-free survival, radiographic evidence of tumor response, and multiple biomarker changes that supported the presence of an immune re...

                            Product Name : IGV-001

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 06, 2022

                            Lead Product(s) : IGV-001,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGV-001,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Me...

                            Details : Study had previously reported a median progression-free survival of 17.1 months in newly diagnosed glioblastoma patients in the highest dose cohort treated with IGV-001, compared with 6.5 months in historical standard-of-care-treated patients (P=0.0025).

                            Product Name : IGV-001

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            April 08, 2022

                            Lead Product(s) : IGV-001,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Imvax

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Imvax

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous GBM Cells,IMV-001,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at AACR Annual Meeting 2022

                            Details : IGV-001 is Imvax’s most advanced product candidate, in development to treat GBM. It has completed a Phase 1a in recurrent glioblastoma and a Phase 1b in newly diagnosed glioblastoma which in total dosed 46 patients.

                            Product Name : IGV-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 09, 2022

                            Lead Product(s) : Autologous GBM Cells,IMV-001,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGV-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imvax to Present Preclinical Data on IGV-001 Mechanism of Action at SITC Annual Meeting

                            Details : The data from in vitro and in vivo studies highlight the effects of IGV-001 on inducing both innate and adaptive immune responses to tumor cells and point to the potential mechanism behind observed clinical activity for IGV-001 in the treatment of gliobl...

                            Product Name : IGV-001

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 21, 2021

                            Lead Product(s) : IGV-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Imvax

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGV-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : HP WILD Holding AG

                            Deal Size : $112.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Imvax Raises $112M to Advance Brain Cancer Cell Therapy

                            Details : Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme, Phase 1 research into additional solid tumor indications and build out of the operational capabilities.

                            Product Name : IGV-001

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            July 16, 2020

                            Lead Product(s) : IGV-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : HP WILD Holding AG

                            Deal Size : $112.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth